Loading
A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL is a phase 1/2 interventional study registered as NCT04521231 by Amgen, with 181 participants enrolled, started 2021-01-04 and due to reach its primary completion in 2027-11-24. Interventions recorded: Blinatumomab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Blinatumomab, BeOne Medicines (formerly BeiGene), Amgen, T-cell engagers (bispecific) and the tag pipeline.
Shares Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/